MCID: TRN018
MIFTS: 61

Transitional Cell Carcinoma

Categories: Rare diseases, Cancer diseases, Nephrological diseases

Aliases & Classifications for Transitional Cell Carcinoma

MalaCards integrated aliases for Transitional Cell Carcinoma:

Name: Transitional Cell Carcinoma 12 76 53 15
Carcinoma, Transitional Cell 44 73
Transitional Cell Neoplasm 12 73
Transitional Cell Carcinoma of Bladder 73
Carcinoma Transitional Cell 55
Urothelial Cell Carcinoma 12
Transitional Cell Tumor 12
Transitional Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2671
MeSH 44 D002295
NCIt 50 C2930 C6783

Summaries for Transitional Cell Carcinoma

Disease Ontology : 12 A carcinoma that derives from transitional epithelial cells.

MalaCards based summary : Transitional Cell Carcinoma, also known as carcinoma, transitional cell, is related to bladder papillary transitional cell neoplasm and renal pelvis transitional cell carcinoma. An important gene associated with Transitional Cell Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and Developmental Biology. The drugs Vinblastine and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include kidney, lymph node and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Transitional cell carcinoma, also urothelial carcinoma, is a type of cancer that typically occurs in the... more...

Related Diseases for Transitional Cell Carcinoma

Diseases related to Transitional Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 351)
# Related Disease Score Top Affiliating Genes
1 bladder papillary transitional cell neoplasm 34.4 FGFR3 KRT20 TP53
2 renal pelvis transitional cell carcinoma 34.4 KRT7 UPK3A
3 small cell carcinoma of the bladder 32.0 KRT20 KRT7
4 bladder urothelial carcinoma 31.8 CDH1 ERBB2 FGFR3 HRAS KRT20 KRT7
5 suppression of tumorigenicity 12 31.1 HRAS PTEN TP53
6 inverted papilloma 30.8 CDKN2A KRT20 KRT7 TP53
7 horseshoe kidney 30.6 EGFR KRT20 KRT7
8 non-invasive bladder papillary urothelial neoplasm 30.6 FGFR3 TP53 UPK3A
9 prostate cancer 30.5 CDH1 EGFR ERBB2 ERBB3 HRAS KRT18
10 clear cell adenocarcinoma 30.5 KRT20 KRT7 TP53
11 myeloma, multiple 30.3 CDKN2A FGFR3 HRAS TP53
12 bladder disease 30.3 UPK1A UPK2 UPK3A
13 linitis plastica 30.2 CDH1 KRT20 KRT7
14 cystadenocarcinoma 30.2 ERBB2 HRAS KRT7 TP53
15 papilloma 30.2 CDKN2A FGFR3 KRT20 KRT7 PTEN TP53
16 papillary adenocarcinoma 30.1 CDH1 ERBB2 KRT7 TP53
17 ovarian cancer 1 29.9 CDH1 ERBB2 HRAS KRT7 TP53
18 mucinous adenocarcinoma 29.8 CDKN2A EGFR KRT20 KRT7
19 renal cell carcinoma, nonpapillary 29.8 CDH1 EGFR IFNA2 KRT20 KRT7
20 small cell carcinoma 29.8 EGFR KRT20 KRT7 PTEN TP53
21 cystitis 29.7 KRT20 PTGS2 TP53 UPK1A UPK3A
22 ovarian brenner tumor 29.6 KRT18 KRT20 KRT7 UPK3A
23 renal cell carcinoma, papillary, 1 29.6 ERBB2 FGFR3 HRAS KRT7 PTEN TP53
24 bladder squamous cell carcinoma 29.5 CDKN2A ERBB2 FGFR3 PTEN PTGS2 TP53
25 bladder cancer 29.2 BRINP1 CDH1 CDKN2A EGFR ERBB2 FGFR3
26 squamous cell carcinoma 29.0 CDH1 CDKN2A EGFR ERBB2 FGFR3 HRAS
27 adenocarcinoma 28.9 CDH1 CDKN2A EGFR ERBB2 ERBB3 FGFR3
28 endometrial cancer 28.6 CDH1 CDKN2A EGFR ERBB2 HRAS KRT7
29 lung cancer 27.2 CDH1 CDKN2A EGFR ERBB2 ERBB3 HRAS
30 sarcomatoid transitional cell carcinoma 12.5
31 prostate transitional cell carcinoma 12.2
32 ureter transitional cell carcinoma 12.2
33 ovary transitional cell carcinoma 12.2
34 invasive bladder transitional cell carcinoma 12.2
35 fallopian tube transitional cell carcinoma 12.2
36 urethra transitional cell carcinoma 12.2
37 non-papillary transitional cell carcinoma of the bladder 12.1
38 bartholin's gland transitional cell carcinoma 12.1
39 endometrial transitional cell carcinoma 12.1
40 transitional cell carcinoma of the corpus uteri 12.1
41 kidney pelvis sarcomatoid transitional cell carcinoma 12.1
42 urinary tract non-invasive transitional cell neoplasm 12.1
43 infiltrating renal pelvis transitional cell carcinoma 12.0
44 infiltrating ureter transitional cell carcinoma 12.0
45 papillary transitional carcinoma 11.9
46 brain stem astrocytic neoplasm 11.1 CDKN2A TP53
47 breast papillomatosis 11.0 CDKN2A ERBB2
48 prostate cancer, hereditary, 1 11.0
49 prostate cancer, hereditary, 12 11.0
50 prostate cancer, hereditary, 13 11.0

Graphical network of the top 20 diseases related to Transitional Cell Carcinoma:



Diseases related to Transitional Cell Carcinoma

Symptoms & Phenotypes for Transitional Cell Carcinoma

GenomeRNAi Phenotypes related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.96 EGFR HRAS
2 Decreased viability GR00221-A-1 9.96 EGFR FGFR3 HRAS CDH1 CDKN2A
3 Decreased viability GR00221-A-2 9.96 FGFR3 HRAS
4 Decreased viability GR00221-A-3 9.96 FGFR3 HRAS CDKN2A
5 Decreased viability GR00221-A-4 9.96 EGFR CDKN2A
6 Decreased viability GR00301-A 9.96 CDH1
7 Decreased viability GR00402-S-2 9.96 EGFR FGFR3 HRAS CDH1 CDKN2A
8 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.55 EGFR ERBB2 FGFR3 HRAS PTEN
9 Reduced mammosphere formation GR00396-S 9.28 ERBB3 HRAS BRINP1 KRT18 CDH1 KRT7

MGI Mouse Phenotypes related to Transitional Cell Carcinoma:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 ERBB2 CDKN2A BRINP1 EGFR CDH1 KRT7
2 growth/size/body region MP:0005378 10.34 ERBB2 CDKN2A BRINP1 EGFR CDH1 FGFR3
3 cellular MP:0005384 10.29 EGFR CDH1 CDKN2A BRINP1 ERBB3 KRT7
4 mortality/aging MP:0010768 10.28 EGFR CDH1 CDKN2A ERBB2 BRINP1 KRT18
5 digestive/alimentary MP:0005381 10.24 ERBB2 CDKN2A EGFR CDH1 FGFR3 PTEN
6 embryo MP:0005380 10.22 CDH1 ERBB2 CDKN2A EGFR PTEN ERBB3
7 endocrine/exocrine gland MP:0005379 10.16 EGFR CDH1 ERBB2 CDKN2A PTEN HRAS
8 integument MP:0010771 10.16 CDH1 ERBB2 CDKN2A EGFR FGFR3 PTEN
9 neoplasm MP:0002006 10.1 ERBB2 CDKN2A EGFR CDH1 FGFR3 PTEN
10 normal MP:0002873 10.02 CDH1 ERBB2 EGFR FGFR3 PTEN HRAS
11 no phenotypic analysis MP:0003012 9.97 EGFR CDH1 CDKN2A BRINP1 FGFR3 HRAS
12 renal/urinary system MP:0005367 9.81 EGFR KRT7 FGFR3 PTEN HRAS UPK3A
13 pigmentation MP:0001186 9.65 EGFR CDKN2A ERBB3 PTEN TP53
14 respiratory system MP:0005388 9.61 ERBB2 CDKN2A EGFR FGFR3 PTEN HRAS
15 skeleton MP:0005390 9.28 EGFR ERBB2 CDKN2A BRINP1 FGFR3 PTEN

Drugs & Therapeutics for Transitional Cell Carcinoma

Drugs for Transitional Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 268)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vinblastine Approved Phase 2, Phase 3,Phase 3,Phase 1 865-21-4 13342 241903
2
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 15663-27-1 84093 441203 2767
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
4
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
5
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
6
Amphotericin B Approved, Investigational Phase 2, Phase 3 1397-89-3 14956 5280965
7
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
8
Valrubicin Approved Phase 3,Phase 2,Phase 1 56124-62-0 41744
9
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
10
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
11
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
12
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 114977-28-5 148124
13
Aminolevulinic acid Approved Phase 3 106-60-5 137
14
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
15
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
16
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
17
Hydroxocobalamin Approved Phase 3,Phase 2 13422-51-0 11953898 44475014
18
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
19
Ramucirumab Approved, Investigational Phase 3,Phase 2,Phase 1 947687-13-0
20
Mannitol Approved, Investigational Phase 3,Phase 2 69-65-8 453 6251
21
Gefitinib Approved, Investigational Phase 3,Phase 2 184475-35-2 123631
22
Pembrolizumab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 1374853-91-4
23
nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
24
Olaparib Approved Phase 3,Phase 2,Phase 1 763113-22-0 23725625
25
Ethanol Approved Phase 3 64-17-5 702
26
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
27
Cephalexin Approved, Investigational, Vet_approved Phase 3 15686-71-2 27447
28
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
30
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
31
Tocopherol Approved, Investigational, Nutraceutical Phase 3 1406-66-2 14986
32
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
33
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 59-67-6 938
34
Nicotinamide Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 98-92-0 936
35
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
36
Cyanocobalamin Approved, Nutraceutical Phase 3,Phase 2 68-19-9 44176380
37
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 3,Phase 2 13422-55-4
38
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1,Phase 2 56-86-0 33032
39
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
40
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 231277-92-2, 388082-78-8 208908 9941095
41
BCG vaccine Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
42
Fenretinide Investigational Phase 3 65646-68-6
43
Levulinic acid Experimental Phase 3 123-76-2 11579
44
Cediranib Investigational Phase 3,Phase 2 288383-20-0 9933475
45
Maleic acid Experimental Phase 3,Phase 2,Not Applicable 110-16-7 444266
46
Apaziquone Investigational Phase 3 114560-48-4 5813717
47 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1
48 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 3,Phase 1
49 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
50 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 500)
# Name Status NCT ID Phase Drugs
1 Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel Unknown status NCT01668459 Phase 2, Phase 3 Cabazitaxel
2 Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU) Unknown status NCT01830231 Phase 2, Phase 3 Cabazitaxel;Vinflunine
3 I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations Unknown status NCT02818725 Phase 3 Chemotherapy;panitumumab
4 Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer Unknown status NCT00146276 Phase 3 gemcitabine
5 Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer Unknown status NCT00867347 Phase 3
6 A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium Unknown status NCT00949455 Phase 2, Phase 3 lapatinib ditosylate
7 Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer Unknown status NCT00553345 Phase 3 selenium;vitamin E
8 Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer Unknown status NCT00553124 Phase 3 selenium;vitamin E
9 Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Unknown status NCT00003725 Phase 3 valrubicin
10 Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer Unknown status NCT00054626 Phase 3 cisplatin;gemcitabine hydrochloride
11 First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy Completed NCT00389155 Phase 2, Phase 3 Vinflunine;Gemcitabine
12 Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium Completed NCT00028756 Phase 3 doxorubicin hydrochloride;gemcitabine hydrochloride;vinblastine sulfate;methotrexate;cisplatin
13 Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract Completed NCT00315237 Phase 3 vinflunine and best supportive care
14 Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer. Completed NCT00330499 Phase 3 Cisplatin
15 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00003701 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate
16 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00014534 Phase 3 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride
17 Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer Completed NCT00004154 Phase 3 Fenretinide
18 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3 Amino levulinic Acid
19 High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer Completed NCT00003623 Phase 3
20 Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer Completed NCT00406068 Phase 2, Phase 3 Mycobacterial cell wall-DNA complex
21 Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer Completed NCT00002490 Phase 3 mitomycin C
22 Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer Completed NCT00729287 Phase 3
23 Surgery and BCG in Treating Patients With Bladder Cancer Completed NCT00002990 Phase 3
24 S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Completed NCT00445601 Phase 3 gemcitabine hydrochloride
25 Eflornithine in Treating Patients With Bladder Cancer Completed NCT00003814 Phase 3 eflornithine
26 Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer Completed NCT00033436 Phase 3 carbogen
27 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
28 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
29 Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed NCT00024349 Phase 3 fluorouracil;mitomycin C
30 Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
31 Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
32 Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma Recruiting NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
33 Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma Recruiting NCT03410693 Phase 2, Phase 3 Rogaratinib (BAY1163877);Chemotherapy
34 Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Recruiting NCT02807636 Phase 3 Atezolizumab;Carboplatin;Gemcitabine;Cisplatin
35 Bladder Cancer Adjuvant Radiotherapy Trial Recruiting NCT02951325 Phase 3
36 The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study Recruiting NCT02793128 Phase 3 MitoGel™ instillations
37 Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Recruiting NCT03193788 Phase 3 pemetrexed;Folic Acid;Vitamin B12 Injection;Dexamethasone
38 A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection Recruiting NCT02450331 Phase 3 Atezolizumab
39 Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer Recruiting NCT03244384 Phase 3
40 An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer Recruiting NCT02632409 Phase 3
41 S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer Recruiting NCT03091660 Phase 3
42 Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer Recruiting NCT01812369 Phase 3 GEMCITABINE CISPLATINE;METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF
43 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
44 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
45 Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC Recruiting NCT02982395 Phase 3 Nanoxel®M;Mitomycin-C
46 A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) Recruiting NCT02603432 Phase 3
47 Transurethral En Bloc Versus Standard Resection of Bladder Tumour Recruiting NCT02993211 Phase 3
48 Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) Active, not recruiting NCT02853305 Phase 3 Cisplatin;Carboplatin;Gemcitabine
49 Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma Active, not recruiting NCT03374488 Phase 3 Pembrolizumab;Epacadostat;Placebo
50 Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) Active, not recruiting NCT03361865 Phase 3 Pembrolizumab;Epacadostat;Placebo

Search NIH Clinical Center for Transitional Cell Carcinoma

Cochrane evidence based reviews: carcinoma, transitional cell

Genetic Tests for Transitional Cell Carcinoma

Anatomical Context for Transitional Cell Carcinoma

MalaCards organs/tissues related to Transitional Cell Carcinoma:

41
Kidney, Lymph Node, Lung, Prostate, Ovary, Testes, Bone

Publications for Transitional Cell Carcinoma

Articles related to Transitional Cell Carcinoma:

(show top 50) (show all 1257)
# Title Authors Year
1
A patient with acquired factor X deficiency and metastatic transitional cell carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumors? ( 29130135 )
2018
2
Coincidental Bladder Cuff Transitional Cell Carcinoma in Nephroureterectomy Specimens: Risk Factors, Prognosis and Clinical Implementation. ( 29687437 )
2018
3
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy. ( 29416444 )
2018
4
In vitro evaluation of a simulated pneumoperitoneum environment using carbon dioxide on canine transitional cell carcinoma. ( 29484672 )
2018
5
Screening for canine transitional cell carcinoma (TCC) by SERS-based quantitative urine cytology. ( 29597048 )
2018
6
Synchronous ipsilateral renal cell carcinoma and transitional cell carcinoma of the renal pelvic with complete remission of TCC after neoadjuvant chemotherapy. ( 29888183 )
2018
7
Prognostic Value of Soluble Death Receptor Ligands in Patients with Transitional Cell Carcinoma of Bladder. ( 29719304 )
2018
8
Quantitative evaluation of canine urinary bladder transitional cell carcinoma using contrast-enhanced ultrasonography. ( 29530040 )
2018
9
Monoinstitutional real world experience in management of Vinflunine as second line therapy for transitional cell carcinoma of the urothelium. ( 29492236 )
2018
10
Cytological Findings of a Rare Case of Transitional Cell Carcinoma Bladder Presenting with Supraclavicular Lymphnode Metastasis. ( 29643666 )
2018
11
LncRNA MALAT1 promotes tumor growth and metastasis by targeting miR-124/foxq1 in bladder transitional cell carcinoma (BTCC). ( 29736319 )
2018
12
Iodine Content Analysis Using Dual-Energy Computed Tomography as a Biomarker of Transitional Cell Carcinoma, an Experience with Separation of the Clotted Blood and Tumorous Tissue. ( 29277821 )
2018
13
Thrombus-like Tumor of Renal Cell Carcinoma Mimicking Transitional Cell Carcinoma of Kidney: A Case Report. ( 27896135 )
2017
14
The expression and clinical significance of ZBTB7 in transitional cell carcinoma of the bladder. ( 29085492 )
2017
15
Transitional Cell Carcinoma of Urinary Bladder Manifesting as Extensive Retroperitoneal and Axillary Lymph Node Metastasis: An Extremely Rare Case Scenario Detected by<sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography Scan. ( 29142358 )
2017
16
Wild-type p53-induced phosphatase 1 is a prognostic marker and therapeutic target in bladder transitional cell carcinoma. ( 28356972 )
2017
17
Impact of BCL2 polymorphisms on survival in transitional cell carcinoma of the bladder. ( 28417194 )
2017
18
Association Between Human Papillomavirus and Transitional Cell Carcinoma of the Bladder. ( 29101759 )
2017
19
Radical Cystectomy and Cutaneous Ureterostomy in 4 Dogs with Trigonal Transitional Cell Carcinoma: Description of Technique and Case Series. ( 27911468 )
2017
20
Huge Prostatic Utricle with Transitional Cell Carcinoma in an Adult. ( 28065811 )
2017
21
Lymph node density in muscle-invasive transitional cell carcinoma of the urinary bladder; De novo versus progressive disease. ( 28936147 )
2017
22
VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland. ( 28098864 )
2017
23
In vitro evaluation of Selective Inhibitors of Nuclear Export (SINE) drugs KPT-185 and KPT-335 against canine mammary carcinoma and transitional cell carcinoma tumor initiating cells. ( 28133930 )
2017
24
The Prognostic Role of NEDD9 and P38 Protein Expression Levels in Urinary Bladder Transitional Cell Carcinoma. ( 28194179 )
2017
25
Urine cell-free microRNA as biomarkers for transitional cell carcinoma. ( 29187235 )
2017
26
A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN). ( 28419193 )
2017
27
Stage IIIC transitional cell carcinoma and serous carcinoma of the ovary have similar outcomes when treated with platinum-based chemotherapy. ( 28506948 )
2017
28
MicroRNA profiling of dogs with transitional cell carcinoma of the bladder using blood and urine samples. ( 29141625 )
2017
29
Expression of Cancer Stem Cell Markers OCT4 and CD133 in Transitional Cell Carcinomas. ( 26945449 )
2017
30
Clinical outcome of partial cystectomy for transitional cell carcinoma of the canine bladder. ( 28217972 )
2017
31
Non-transitional cell carcinoma of the upper urinary tract: A case series among 305 cases at a tertiary urology institute. ( 28216943 )
2017
32
Cancer-Testis Antigens as New Candidate Diagnostic Biomarkers for Transitional Cell Carcinoma of Bladder. ( 29058301 )
2017
33
Overexpression of HER-2 via immunohistochemistry in canine urinary bladder transitional cell carcinoma - A marker of malignancy and possible therapeutic target. ( 28871659 )
2017
34
Microcystic transitional cell carcinoma: a rare tumor of the urinary bladder. ( 29154374 )
2017
35
Expression of receptor tyrosine kinase targets PDGFR-I^, VEGFR2 and KIT in canine transitional cell carcinoma. ( 28884928 )
2017
36
Lymph node yield in node-negative patients predicts cancer specific survival following radical cystectomy for transitional cell carcinoma. ( 29124240 )
2017
37
Transitional Cell Carcinoma of Lacrimal Sac. ( 28582372 )
2017
38
Transitional cell carcinoma involving graft kidney in a kidney transplant recipient: a case report. ( 28934936 )
2017
39
Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma. ( 27878359 )
2017
40
High-grade transitional cell carcinoma masquerading as a xanthogranulomatous pyelonephritis and perinephric abscess. ( 28491170 )
2017
41
ODF4, MAGEA3, and MAGEB4: Potential Biomarkers in Patients with Transitional Cell Carcinoma ( 28865418 )
2017
42
Re: Patterns of Recurrence in Upper Tract Transitional Cell Carcinoma: Imaging Surveillance. ( 29539888 )
2017
43
Prognostic factors and outcomes of primary transitional cell carcinoma of the ureter: a population-based study. ( 29029487 )
2017
44
Density of tumor-infiltrating granzyme B-positive cells predicts favorable prognosis in dogs with transitional cell carcinoma. ( 28778323 )
2017
45
Association between chromosomal aberration of exfoliated bladder cells in the urine and oxidative stress in patients with bladder transitional cell carcinoma. ( 28693145 )
2017
46
Transitional cell carcinoma of the renal pelvis with venous tumor thrombus. ( 28959157 )
2017
47
Cytological diagnosis of a rare case of cutaneous metastasis from transitional cell carcinoma, renal pelvis. ( 29233453 )
2017
48
Bladder chondrosarcoma plus urothelial carcinoma in recurred transitional cell carcinoma of the upper urinary tract: a case report and literature review. ( 27765044 )
2016
49
A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma. ( 27855679 )
2016
50
Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder. ( 27228294 )
2016

Variations for Transitional Cell Carcinoma

Copy number variations for Transitional Cell Carcinoma from CNVD:

7 (show top 50) (show all 92)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 26136 1 197500000 205300000 Amplification LRRN2 Urothelial cell carcinoma
2 26141 1 197500000 205300000 Amplification MDM4 Urothelial cell carcinoma
3 26154 1 197500000 205300000 Loss Urothelial cell carcinoma
4 42679 10 3800000 6700000 Amplification PFKFB3 Urothelial cell carcinoma
5 49670 11 110000000 115400000 Loss ANKK1 Urothelial cell carcinoma
6 49671 11 110000000 115400000 Loss DRD2 Urothelial cell carcinoma
7 49672 11 110000000 115400000 Loss NCAM1 Urothelial cell carcinoma
8 49673 11 110000000 115400000 Loss TTC12 Urothelial cell carcinoma
9 52333 11 16100000 21600000 Loss PLEKHA7 Urothelial cell carcinoma
10 58688 11 69200000 70700000 Amplification CCND1 Urothelial cell carcinoma
11 58689 11 69200000 70700000 Amplification FGF19 Urothelial cell carcinoma
12 58690 11 69200000 70700000 Amplification FGF3 Urothelial cell carcinoma
13 58692 11 69200000 70700000 Amplification FGF4 Urothelial cell carcinoma
14 58694 11 69200000 70700000 Amplification ORAOV1 Urothelial cell carcinoma
15 58695 11 69200000 70700000 Amplification TPCN2 Urothelial cell carcinoma
16 58889 11 70700000 74900000 Amplification Urothelial cell carcinoma
17 58890 11 70700000 74900000 Amplification C11orf76 Urothelial cell carcinoma
18 58891 11 70700000 74900000 Amplification SHANK2 Urothelial cell carcinoma
19 64483 12 128700000 132349534 Loss FZD10 Urothelial cell carcinoma
20 69470 12 55200000 56300000 Amplification ARHGAP9 Urothelial cell carcinoma
21 69471 12 55200000 56300000 Amplification DCTN2 Urothelial cell carcinoma
22 69472 12 55200000 56300000 Amplification GLI1 Urothelial cell carcinoma
23 69473 12 55200000 56300000 Amplification INHBC Urothelial cell carcinoma
24 69474 12 55200000 56300000 Amplification KIF5A Urothelial cell carcinoma
25 69475 12 55200000 61400000 Amplification CDK4 Urothelial cell carcinoma
26 69476 12 55200000 61400000 Amplification METTL1 Urothelial cell carcinoma
27 69477 12 55200000 61400000 Amplification TSFM Urothelial cell carcinoma
28 69795 12 56300000 61400000 Amplification FAM19A2 Urothelial cell carcinoma
29 69796 12 56300000 61400000 Amplification SLC16A7 Urothelial cell carcinoma
30 70900 12 66000000 69800000 Amplification CNOT2 Urothelial cell carcinoma
31 70901 12 66000000 69800000 Amplification CPM Urothelial cell carcinoma
32 70902 12 66000000 69800000 Amplification IFNG Urothelial cell carcinoma
33 70903 12 66000000 69800000 Amplification IL22 Urothelial cell carcinoma
34 70904 12 66000000 69800000 Amplification IL26 Urothelial cell carcinoma
35 70910 12 66000000 69800000 Amplification MDM2 Urothelial cell carcinoma
36 70911 12 66000000 69800000 Amplification TM4SF3 Urothelial cell carcinoma
37 71411 12 69800000 74100000 Amplification LGR5 Urothelial cell carcinoma
38 71412 12 69800000 74100000 Amplification THAP2 Urothelial cell carcinoma
39 71413 12 69800000 74100000 Amplification TMEM19 Urothelial cell carcinoma
40 71414 12 69800000 74100000 Amplification TPH2 Urothelial cell carcinoma
41 71668 12 74100000 78700000 Amplification NAV3 Urothelial cell carcinoma
42 72907 12 87500000 91200000 Amplification KITLG Urothelial cell carcinoma
43 73109 12 91200000 94800000 Amplification PLXNC1 Urothelial cell carcinoma
44 79797 13 77800000 86500000 Loss Urothelial cell carcinoma
45 94764 15 70400000 73100000 Loss SDFR1 Urothelial cell carcinoma
46 109762 17 28800000 35600000 Amplification ERBB2 Urothelial cell carcinoma
47 109763 17 28800000 35600000 Amplification TCAP Urothelial cell carcinoma
48 123109 18 66900000 71300000 Loss Urothelial cell carcinoma
49 123110 18 66900000 71300000 Loss SDCCAG33 Urothelial cell carcinoma
50 123111 18 66900000 71300000 Loss ZADH2 Urothelial cell carcinoma

Expression for Transitional Cell Carcinoma

Search GEO for disease gene expression data for Transitional Cell Carcinoma.

Pathways for Transitional Cell Carcinoma

Pathways related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 CDH1 CDKN2A EGFR ERBB2 ERBB3 FGFR3
2
Show member pathways
13.52 EGFR ERBB2 ERBB3 FGFR3 HRAS KRT18
3
Show member pathways
13.48 CDH1 EGFR ERBB2 ERBB3 FGFR3 HRAS
4
Show member pathways
13.37 EGFR ERBB2 ERBB3 FGFR3 HRAS IFNA2
5
Show member pathways
13.12 EGFR ERBB2 ERBB3 FGFR3 PTEN TP53
6
Show member pathways
12.95 CDH1 EGFR ERBB2 ERBB3 FGFR3
7
Show member pathways
12.91 EGFR ERBB2 ERBB3 FGFR3 HRAS IFNA2
8
Show member pathways
12.88 EGFR ERBB2 ERBB3 FGFR3 HRAS PTEN
9
Show member pathways
12.87 CDH1 CDKN2A EGFR ERBB2 HRAS PTEN
10
Show member pathways
12.8 EGFR ERBB2 ERBB3 HRAS PTEN
11 12.76 EGFR ERBB2 ERBB3 FGFR3 HRAS TP53
12
Show member pathways
12.76 CDH1 CDKN2A EGFR ERBB2 HRAS PTEN
13
Show member pathways
12.71 EGFR ERBB2 ERBB3 FGFR3 HRAS PTEN
14
Show member pathways
12.67 CDH1 ERBB2 ERBB3 HRAS PTEN PTGS2
15
Show member pathways
12.64 CDH1 CDKN2A EGFR ERBB2 ERBB3 FGFR3
16
Show member pathways
12.59 HRAS IFNA2 PTEN PTGS2 TP53
17 12.58 CDH1 CDKN2A EGFR ERBB2 FGFR3 HRAS
18
Show member pathways
12.55 CDH1 EGFR ERBB2 ERBB3 HRAS TP53
19
Show member pathways
12.48 EGFR ERBB2 ERBB3 HRAS TP53
20
Show member pathways
12.46 EGFR ERBB2 ERBB3 FGFR3 HRAS PTEN
21
Show member pathways
12.44 EGFR ERBB2 ERBB3 FGFR3 HRAS TP53
22
Show member pathways
12.33 EGFR ERBB2 ERBB3 HRAS
23
Show member pathways
12.33 EGFR ERBB2 ERBB3 HRAS PTGS2
24 12.31 EGFR ERBB2 ERBB3 HRAS TP53
25
Show member pathways
12.25 EGFR FGFR3 HRAS PTEN
26 12.21 CDH1 EGFR PTGS2 TP53
27 12.21 EGFR ERBB2 HRAS PTEN
28 12.19 CDKN2A HRAS PTEN TP53
29 12.17 CDH1 EGFR PTEN TP53
30
Show member pathways
12.16 EGFR ERBB2 HRAS PTEN
31 12.15 EGFR ERBB2 ERBB3 FGFR3
32
Show member pathways
12.13 EGFR ERBB2 HRAS PTEN
33 12.1 EGFR ERBB2 ERBB3 FGFR3 HRAS PTEN
34
Show member pathways
12.08 EGFR ERBB2 ERBB3 FGFR3
35 12.08 CDKN2A EGFR ERBB2 ERBB3 FGFR3 HRAS
36 12.07 EGFR HRAS IFNA2 TP53
37
Show member pathways
12.06 EGFR ERBB2 ERBB3 HRAS
38
Show member pathways
12.04 EGFR ERBB2 ERBB3 TP53
39 11.97 CDKN2A ERBB2 HRAS PTEN TP53
40
Show member pathways
11.96 EGFR ERBB2 ERBB3 HRAS
41 11.95 CDKN2A HRAS PTEN TP53
42 11.92 CDKN2A EGFR HRAS PTEN TP53
43 11.86 PTEN PTGS2 TP53
44 11.75 CDKN2A ERBB2 TP53
45 11.74 CDH1 EGFR ERBB2
46 11.71 ERBB2 HRAS PTEN TP53
47 11.62 EGFR ERBB2 ERBB3 HRAS
48 11.58 CDKN2A EGFR TP53
49 11.55 EGFR ERBB2 FGFR3 HRAS PTEN TP53
50 11.54 EGFR HRAS PTGS2

GO Terms for Transitional Cell Carcinoma

Cellular components related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.76 BRINP1 EGFR FGFR3 PTGS2 TP53 UBIAD1
2 receptor complex GO:0043235 9.62 EGFR ERBB2 ERBB3 FGFR3
3 apical plasma membrane GO:0016324 9.23 EGFR ERBB2 ERBB3 PTEN UPK1A UPK1B
4 basal plasma membrane GO:0009925 9.13 EGFR ERBB2 ERBB3
5 cytoplasm GO:0005737 10.13 BRINP1 CDH1 CDKN2A EGFR ERBB2 ERBB3

Biological processes related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.98 EGFR ERBB2 HRAS PTEN TP53
2 positive regulation of gene expression GO:0010628 9.93 CDKN2A ERBB2 ERBB3 HRAS PTEN TP53
3 MAPK cascade GO:0000165 9.92 EGFR ERBB2 ERBB3 FGFR3 HRAS
4 peptidyl-tyrosine phosphorylation GO:0018108 9.88 EGFR ERBB2 ERBB3 FGFR3
5 positive regulation of protein kinase B signaling GO:0051897 9.86 EGFR ERBB2 ERBB3 FGFR3
6 cell cycle arrest GO:0007050 9.85 BRINP1 CDKN2A HRAS TP53
7 negative regulation of signal transduction GO:0009968 9.84 EGFR ERBB2 ERBB3 FGFR3
8 wound healing GO:0042060 9.81 EGFR ERBB2 ERBB3
9 phosphatidylinositol phosphorylation GO:0046854 9.8 EGFR ERBB2 ERBB3 FGFR3
10 Ras protein signal transduction GO:0007265 9.79 CDKN2A HRAS TP53
11 positive regulation of MAP kinase activity GO:0043406 9.77 EGFR ERBB2 HRAS
12 positive regulation of epithelial cell proliferation GO:0050679 9.77 EGFR ERBB2 HRAS
13 epithelial cell differentiation GO:0030855 9.73 UPK1A UPK1B UPK2 UPK3A
14 cell surface receptor signaling pathway GO:0007166 9.73 EGFR ERBB2 HRAS IFNA2 UPK1A UPK1B
15 positive regulation of MAPK cascade GO:0043410 9.72 EGFR ERBB2 ERBB3 FGFR3 HRAS
16 positive regulation of kinase activity GO:0033674 9.71 EGFR ERBB2 ERBB3 FGFR3
17 regulation of cell motility GO:2000145 9.69 EGFR ERBB2 ERBB3
18 replicative senescence GO:0090399 9.63 CDKN2A TP53
19 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.63 EGFR ERBB2 ERBB3 FGFR3 HRAS PTEN
20 negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031658 9.61 CDKN2A PTEN
21 negative regulation of immature T cell proliferation in thymus GO:0033088 9.57 CDKN2A ERBB2
22 negative regulation of ERBB signaling pathway GO:1901185 9.54 EGFR ERBB2 ERBB3
23 ERBB2 signaling pathway GO:0038128 9.26 EGFR ERBB2 ERBB3 HRAS
24 negative regulation of apoptotic process GO:0043066 9.23 EGFR ERBB2 ERBB3 FGFR3 KRT18 PTEN
25 multicellular organism development GO:0007275 10.17 CDH1 EGFR ERBB2 ERBB3 FGFR3 TP53
26 positive regulation of cell proliferation GO:0008284 10.03 EGFR FGFR3 HRAS PTEN PTGS2
27 apoptotic process GO:0006915 10.02 CDKN2A FGFR3 HRAS IFNA2 KRT20 PTEN
28 negative regulation of cell proliferation GO:0008285 10.01 CDKN2A HRAS PTEN PTGS2 TP53

Molecular functions related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.88 EGFR ERBB2 ERBB3 FGFR3 HRAS
2 protein tyrosine kinase activity GO:0004713 9.73 EGFR ERBB2 ERBB3 FGFR3
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.71 EGFR ERBB2 ERBB3 FGFR3
4 protein phosphatase binding GO:0019903 9.67 EGFR ERBB2 TP53
5 MAP kinase kinase kinase activity GO:0004709 9.62 EGFR ERBB2 ERBB3 FGFR3
6 mitogen-activated protein kinase kinase binding GO:0031434 9.56 EGFR ERBB2 ERBB3 FGFR3
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.46 EGFR ERBB2 ERBB3 FGFR3
8 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.26 EGFR ERBB2 ERBB3 FGFR3
9 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 8.8 EGFR ERBB2 ERBB3
10 protein binding GO:0005515 10.35 BRINP1 CDH1 CDKN2A EGFR ERBB2 ERBB3
11 identical protein binding GO:0042802 10 CDH1 EGFR ERBB2 ERBB3 FGFR3 PTEN

Sources for Transitional Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....